Date clarification: Today is Tuesday, July 28, 2026. The event metadata supplied lists a July 28, 2026 Q2 earnings event, while “tomorrow” would be July 29, 2026. This preview is therefore framed for the imminent Q2 release/call.
BXP enters Q2 with a credible operating-recovery narrative: premier CBD office leasing improved in Q1, occupancy rose, and a large signed-but-not-commenced lease backlog pointed toward a meaningful 2026–27 cash-flow ramp. The Q2 result needs to show that this recovery is converting from leasing activity into occupied space, rent commencement, and same-property NOI growth—not merely signed leases.
The near-term numerical bar is management’s own Q2 FFO guidance of $1.69–$1.71 per share, versus $1.59 reported in Q1. A result within that range will be less important than whether BXP can sustain its year-end occupancy and leasing targets while progressing asset sales, deleveraging, and the recapitalization of 343 Madison Avenue.
BXP shares closed at $69.23 on July 27, up roughly 2.6% from year-end 2025 and substantially above the March lows. That recovery suggests investors are already assigning greater credibility to the office-leasing and AI-demand thesis; the burden is increasingly on BXP to demonstrate continued operational delivery.
| Key metric / objective | Latest disclosed position |
|---|---|
| Q2 2026 FFO guidance | $1.69–$1.71/share |
| FY 2026 FFO guidance | $6.90–$7.04/share |
| Q1 FFO | $1.59/share |
| Q1 total occupancy | 87.4%, up 70 bps QoQ |
| Q1 leased rate | 90.9%, up 150 bps QoQ |
| Leased-to-occupied gap | 350 bps / ~1.6 million sq. ft. |
| 2026 year-end occupancy objective | About 89% |
| 2027 year-end occupancy objective | About 91% |
| 2026 leasing target | At least 4.0 million sq. ft. |
| Asset-sale proceeds since September 2025 Investor Day | About $1.2 billion net |
| Potential additional 2026 asset-sale proceeds discussed in Q1 | Up to ~$400 million |
| BXP-share net debt / annualized EBITDAre | 8.5x at March 31 |
The most consequential disclosure will be progress from leased to occupied space. At March 31, BXP had a 350-bp gap between its 90.9% leased rate and 87.4% occupancy rate, representing roughly 1.6 million square feet of signed leases not yet contributing fully to GAAP revenue.
Management said roughly 90% of this backlog was expected to commence during 2026. On the Q1 call, it highlighted 1.44 million square feet of executed leases on vacant space expected to begin in the remaining three quarters of 2026. That creates a relatively visible path to higher occupancy and, importantly, a stronger run-rate entering 2027.
What would be constructive - Another sequential increase in occupancy, especially in New York and San Francisco. - Confirmation that the bulk of 2026 commencements remain on schedule. - Better-than-expected near-term move-ins or immediate-revenue leases. - Evidence that the year-end ~89% occupancy target remains intact or has upside.
What would concern investors - Delayed tenant build-outs or lease commencements. - Occupancy gains driven primarily by asset dispositions or assets removed from service rather than organic leasing. - A growing gap between executed leases and actual cash-rent commencement.
BXP executed 1.15 million square feet of leases in Q1 and reported 1.5 million square feet completed by the April 29 earnings call. Management also cited 1.7 million square feet under negotiation and another 1.4 million square feet in active discussions. The company’s stated target is at least 4 million square feet for 2026.
The key question for Q2 is whether the healthy activity is translating into economically attractive leases. Q1 second-generation cash-rent spreads were negative: gross rents declined 1.9% and net rents declined 3.2%. This does not invalidate the recovery thesis—BXP is prioritizing occupancy and future cash flow—but it illustrates that demand strength has not yet translated uniformly into broad pricing power.
Investors should look for: - Second-generation cash-rent spreads, both companywide and by market. - Free-rent and tenant-improvement requirements, particularly on the West Coast. - The mix between renewals, expansions, new clients, and backfills of vacancy. - Leasing progress at high-value vacant blocks, where incremental occupancy should carry disproportionate NOI value.
BXP’s strongest market signals in Q1 came from: - New York: 360 Park Avenue South was 90% leased at quarter-end and management subsequently described an expansion that would bring it to roughly 95% leased; 200 Fifth Avenue and Times Square Tower also had material leasing activity. - San Francisco: 680 Folsom had substantial leasing momentum, with AI- and tech-related activity supporting demand. - Reston / Northern Virginia: occupancy remained very high, with continued activity from defense contractors and professional-services users. - Boston: CBD performance remained strong, although the company’s suburban/urban-edge exposure remains more mixed.
Management’s Q1 commentary was unusually constructive on AI-related office demand. It cited direct leasing to AI companies and indirect demand from clients serving the AI ecosystem, particularly in San Francisco, New York, and Seattle. BXP also characterized AI demand in San Francisco as the major driver of market activity and said Midtown South AI leasing had accelerated year over year.
This is strategically meaningful because BXP’s portfolio is concentrated in high-quality CBD buildings within gateway markets. Its premise is that these assets are better positioned than the broader office market to capture tenants that are expanding, upgrading space, and enforcing more in-person work.
However, investors should distinguish between:
1. A few high-profile AI leases, which can improve sentiment and fill specific vacancies; and
2. Sustained broad-based demand, which is needed to support rent growth and a durable office-cycle recovery.
Q2 commentary on the depth of AI requirements, the pace of legal/documentation processes, and whether demand is spreading beyond a small group of tenants will matter.
290 Binney Street is an important near-term catalyst. The 573,000-square-foot Cambridge life-sciences project is 100% leased to AstraZeneca, and management said AstraZeneca began cash-rent payments on April 1, 2026. BXP expected delivery by June 1, more than a month ahead of prior expectations.
For Q2, investors should assess: - Whether delivery occurred on schedule. - The immediate NOI contribution versus the offset from lower capitalized interest after delivery. - Whether project costs remained within budget.
The much larger longer-term issue is 343 Madison Avenue in New York. At Q1, the 930,000-square-foot development was 29% committed, with leases under negotiation that could bring commitments to roughly 56%. Management also intended to complete a project recapitalization during 2026, potentially with multiple equity partners, alongside construction financing.
Positive Q2 developments would include: - Signed leases converting the negotiation pipeline into committed occupancy. - Greater clarity on the timing, economics, and ownership structure of the recapitalization. - Confirmation that construction costs, procurement savings, and projected 7.5%–8.0% stabilized unlevered cash return remain on track.
The risk is that delayed leasing or a less attractive capital-partner transaction forces BXP to retain more development exposure while it is simultaneously trying to delever.
BXP has positioned dispositions as a deliberate portfolio optimization and balance-sheet strategy—not a one-off source of gains. Since its September 2025 Investor Day, it had generated approximately $1.2 billion of aggregate net sale proceeds through Q1. It had also discussed potential for up to another $400 million of net proceeds during 2026, primarily from nonstrategic office and land after substantially completing its residential disposition program.
The Q2 report should clarify: - Dispositions closed during the quarter and pricing achieved. - Assets under contract or newly marketed. - Use of proceeds: debt repayment, development funding, and/or liquidity preservation. - Whether office transaction-market liquidity is improving enough to support future sales at acceptable valuations.
This matters because BXP’s leverage remains elevated. At March 31, BXP’s share of net debt to annualized EBITDAre was 8.5x, up from 7.9x at year-end. The company had $15.3 billion of BXP-share debt and a meaningful 2026 maturity profile, including a $1.0 billion unsecured note due in October, commercial paper, and a smaller term loan. It also had substantial liquidity through its credit facility, but asset-sale execution remains essential to its deleveraging narrative.
Management’s Q2 FFO target is $1.69–$1.71 per share, while full-year guidance is $6.90–$7.04. Given Q1 FFO of $1.59 and Q2 midpoint guidance of $1.70, the current full-year midpoint implies a stronger second half as lease commencements and development contributions build.
A simple framework:
That implied H2 acceleration makes the occupancy conversion story particularly important. A modest Q2 FFO beat without higher confidence in occupancy, commencements, and 2027 same-property NOI may not be sufficient to change the valuation debate.
Watch for revisions to: - Average in-service occupancy assumptions. - Same-property NOI growth assumptions; the Q1 full-year range was 1.4%–2.4% excluding termination income. - Interest-expense assumptions, especially given the company’s use of commercial paper and the interest-rate environment. - Disposition assumptions and associated lost NOI. - Timing and contribution from 290 Binney and other developments.
BXP’s quarterly dividend is $0.70 per share. While the dividend is not the immediate focal point, the Q1 cash-flow profile underscored the cost of improving occupancy: FAD was $88.7 million, and the reported FAD payout ratio was 140%. That was influenced by unusually high lease commencements and $178 million of second-generation tenant-improvement and leasing-commission spending.
Management indicated Q1 was unusually heavy but expected full-year leasing costs to exceed $400 million as occupancy rises. Investors should therefore monitor whether: - Leasing costs normalize after the Q1 commencement surge; - FAD improves as leases begin paying rent; and - asset-sale proceeds and liquidity are being used to bridge a capital-intensive recovery.
This is less a near-term dividend-call risk than a reminder that the office recovery requires upfront investment before it produces full cash-flow benefits.
The Q2 report is a test of whether BXP’s office-recovery thesis is becoming tangible. The company has already demonstrated stronger leasing and modest occupancy improvement, but the next phase requires cash-rent commencement, better same-property NOI, continuing disposition execution, and visible deleveraging.
The highest-value disclosures will be the change in occupancy, the timing of the 1.6 million-square-foot leased backlog, leasing economics in New York and San Francisco, 290 Binney’s contribution, progress at 343 Madison, and the extent to which asset sales are translating into lower leverage.